Effectiveness & Safety Study of Pentosan Polysulfate Sodium for

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.

Clinical Trial Description

The purpose of this multi-center, double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), randomized (patients are assigned different treatments based on chance), parallel group trial is to evaluate the effectiveness and safety of two doses of pentosan polysulfate sodium (100 mg once a day and 100 mg three times a day) versus placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis. The hypothesis of the study is that there is no treatment difference in the proportion of responders at study endpoint (Week 24). Effectiveness will be assessed based on the reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) total score. Safety assessments include vital signs, laboratory tests, adverse events and physical exams. Patients will receive one of the following study treatments by mouth each day for 24 weeks: pentosan polysulfate sodium 100 mg once a day group - one pentosan polysulfate sodium 100 mg capsule in the morning, and one matching placebo capsule in the afternoon and evening; pentosan polysulfate sodium 100 mg capsule three times a day group - one pentosan polysulfate sodium 100 mg capsule in the morning, afternoon and evening; placebo group - one placebo capsule in the morning, afternoon and evening ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00086684
Study type	Interventional
Source	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status	Terminated
Phase	Phase 4
Start date	September 2003
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04313972` - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone	Phase 4
Completed	`NCT03282318` - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis	Phase 2
Completed	`NCT03463499` - The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients	N/A
Completed	`NCT02898220` - Trans-MAPP II Study of Urologic Chronic Pelvin Pain
Terminated	`NCT02591199` - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome	Phase 2
Completed	`NCT02247557` - Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis	Phase 2
Active, not recruiting	`NCT01731470` - Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)	N/A
Completed	`NCT01197261` - OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)	Phase 2
Completed	`NCT00971568` - Urinary Biomarkers Characteristic to Interstitial Cystitis	N/A
Completed	`NCT00527917` - A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.	Phase 2
Completed	`NCT00150488` - URACYST® For the Treatment of GAG Deficient Interstitial Cystitis	N/A
Recruiting	`NCT00094874` - Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms	Phase 3
Recruiting	`NCT04845217` - Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome	Phase 1/Phase 2
Completed	`NCT04401176` - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	Phase 2
Recruiting	`NCT05147779` - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis	Phase 1
Suspended	`NCT04450316` - Low-dose Naltrexone for Bladder Pain Syndrome	Phase 2
Completed	`NCT04010513` - Hypnosis for Bladder Pain Syndrome	N/A
Completed	`NCT05179460` - A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Completed	`NCT02232282` - Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial	N/A
Completed	`NCT00546858` - Relationship of Interstitial Cystitis to Vulvodynia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms